RxDoctor Payments Data

Christi Baker, MD

Dermatology · Amarillo, TXNPI 1275858433

Payments from drug & device makers

$1,287in general payments, 2019–2025

Across 62 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$196
  • Bristol Myers Squibb$186
  • Amgen$172
  • Sun Pharmaceutical Industries Inc.$165
  • Genentech USA, Inc.$160
  • Johnson & Johnson$67
  • plus $341 from 9 others

What the payments were for

  • Food & beverage$1,287100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie10$196
Bristol Myers Squibb12$186
Amgen7$172
Sun Pharmaceutical Industries Inc.7$165
Genentech USA, Inc.4$160
Johnson & Johnson5$67
Prugen, Inc. Pharmaceuticals2$65
Biofrontera Inc.3$64
Lilly USA, LLC3$58
Novartis3$56
Mayne Pharma Commercial LLC1$25
Pfizer2$24
Aclaris Therapeutics, Inc.1$21
Sanofi1$15
DUSA Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,287 in reported general payments places this provider in the 25th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$709,296
Medicare patients
1,705
Services billed
9,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast45$210,478
Humira(Cf) PenAdalimumab21$137,818
Dupixent PenDupilumab30$111,457
Dupixent SyringeDupilumab12$51,538
Metronidazole88$3,986
Mometasone Furoate208$3,789
Ketoconazole197$3,627
Doxycycline Monohydrate209$2,914
Fluorouracil47$2,816
Tacrolimus18$2,798
Clobetasol Propionate77$2,516
ValacyclovirValacyclovir Hcl56$1,907
Triamcinolone Acetonide145$1,871
Betamethasone Dipropionate36$1,627
Clindamycin Phosphate49$1,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$172$210,47845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →